Long-term experience of steroid-free pediatric renal transplantation: Effects on graft function, body mass index, and longitudinal growth

2013 ◽  
Vol 18 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Per Wittenhagen ◽  
Helle C. Thiesson ◽  
François Baudier ◽  
Erik B. Pedersen ◽  
Mette Neland
Keyword(s):  
Body Mass Index ◽  
Renal Transplantation ◽  
Body Mass ◽  
Graft Function ◽  
Longitudinal Growth ◽  
Pediatric Renal Transplantation ◽  
Long Term Experience

Avoiding steroids in pediatric renal transplantation: Long-term experience from a single centre

2007 ◽  
Vol 11 (7) ◽  
pp. 730-735 ◽  
Author(s):  
Erik Bo Pedersen ◽  
Mohamad El-Faramawi ◽  
Nils Foged ◽  
Karl-Egon Larsen ◽  
Bente Jespersen
Keyword(s):  
Renal Transplantation ◽  
Pediatric Renal Transplantation ◽  
Single Centre ◽  
Long Term Experience

Development of growth and body mass index after pediatric renal transplantation

2005 ◽  
Vol 9 (4) ◽  
pp. 445-449 ◽  
Author(s):  
Udo Vester ◽  
Antonia Schaefer ◽  
Birgitta Kranz ◽  
Anne-Margret Wingen ◽  
Silvio Nadalin ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Renal Transplantation ◽  
Body Mass ◽  
Pediatric Renal Transplantation

Body mass index and allograft function in pediatric renal transplantation

2002 ◽  
Vol 17 (7) ◽  
pp. 535-539 ◽  
Author(s):  
Mark M. Mitsnefes ◽  
Philip Khoury ◽  
Paul T. McEnery
Keyword(s):  
Body Mass Index ◽  
Renal Transplantation ◽  
Body Mass ◽  
Pediatric Renal Transplantation ◽  
Allograft Function

scholarly journals Changes in body mass index after pediatric renal transplantation

2020 ◽  
Vol 31 (2) ◽  
pp. 448
Author(s):  
Ehsan Valavi ◽  
SeyedSeifollah Beladi Mousavi ◽  
Majid Aminzadeh ◽  
Heshmatollah Shahbazian ◽  
Hasan Otukesh ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Renal Transplantation ◽  
Body Mass ◽  
Pediatric Renal Transplantation

scholarly journals Changes in body mass index and outcomes after kidney transplantation: a single centre, retrospective, observational study

2019 ◽  
Author(s):  
Adam Arshad ◽  
James Hodson ◽  
Khalid Khalil ◽  
Adnan Sharif
Keyword(s):  
Body Mass Index ◽  
Kidney Transplantation ◽  
Body Mass ◽  
Geometric Mean ◽  
Graft Function ◽  
Estimating Equation ◽  
Kidney Transplant Recipients ◽  
Long Term Outcomes ◽  
Post Transplant

Abstract Background The aim of this study was to describe the changes in body mass index (BMI) after kidney transplantation and assess how this influences long-term outcomes. Methods Data were collected for all kidney transplant recipients between January 2007 and July 2016. Changes in BMI over the post-transplant period were modelled using a generalised estimating equation. The change in BMI from pre-transplantation to six months was then calculated for each patient. These were categorised into three groups: stable BMI (a change of ±1.5 kg/m2), BMI reduction and BMI increase (changes of >1.5 kg/m2), between which a range of outcomes were compared. Results Data was available for 1,344 patients, who had a geometric mean pre-transplant BMI of 27.3 kg/m2. This declined significantly (P<0.001), to a geometric mean of 25.6 kg/m2 one month after transplantation, before increasing and stabilising to pre-transplant levels by 36 months (geometric mean 27.2 kg/m2, P=0.522). The n=882 patients with BMI measurements at six months, were divided into groups of reduced (n=303), stable (n=388) and increased (n=131) BMI, relative to pre-transplantation levels. On multivariate analysis, 12-month creatinine levels were significantly higher in the BMI reduction cohort, with adjusted levels of 160.6 μmol/l, compared to 135.0 μmol/l in stable BMI. However, no significant associations were detected between six-month BMI change and patient survival, graft survival, incidence of post-transplant diabetes, cancer, or a range of clinical and histological outcomes (all P>0.05). Conclusions Our data demonstrates that BMI significantly reduces in the first month after kidney transplantation, before increasing to pre-transplant levels at 3-5 years. Furthermore, patients with decreasing BMI at six-months have impaired graft function in the long-term. These observations conflict with the existing literature and warrant further investigation.

scholarly journals Feasibility and impact of laparoscopic sleeve gastrectomy after renal transplantation on comorbidities, graft function and quality of life.

2020 ◽  
Author(s):  
Naif Alenazi ◽  
Khaled S Ahmad ◽  
Ilham A Elsamahy ◽  
Mohamed S Essa
Keyword(s):  
Quality Of Life ◽  
Body Mass Index ◽  
Sleeve Gastrectomy ◽  
Renal Transplantation ◽  
Laparoscopic Sleeve Gastrectomy ◽  
Body Mass ◽  
Demographic Data ◽  
Graft Function ◽  
Diabetic Patients

Abstract Background The aim of this study is to clarify the feasibility and effect of laparoscopic sleeve gastrectomy (LSG) on comorbidities, graft function and quality of life in patients under went renal transplantation (RT) Methods This is a retrospective review of 5 patients who underwent laparoscopic sleeve gastrectomy (LSG) after kidney transplantation. Patients demographic data, anthropometric parameters, effect on comorbidities, postoperative course, immunosuppressive medications, cause of renal transplantation (RT), renal function, survival of graft, and post-sleeve gastrectomy quality of life in obese patients with history of renal transplantation (RT) were assessed using BAROS–Moorhead–Ardelt survey Results From September 2015 to September, 2019, 5 renal transplant patients underwent underwent laparoscopic sleeve gastrectomy (LSG); 60% were female and 40 were male with an average body mass index (BMI) before surgery of 41.28 ± 5.8 kg/m2 (range 36–55). Associated comorbidities: 100% of the patients had hypertension (HTN) and dyslipidemia (DSL), Whereas 3 patients (60%) had type 2 diabetes mellitus (T2D) and 1 patient had gout (20%). The average time between renal transplantation (RT) and laparoscopic sleeve gastrectomy (LSG) was 5.6 ± 5 years (range 3–9). Average operative duration was 61 ± 16.5 min (range 50–70), and there were neither postoperative morbidity nor mortality. At 17.9 ± 13.6 months (range 7–48) of follow-up period, body mass index (BMI) was 28.8 ± 6.3 kg/m2 (range 25–42). Regarding patients with hypertension (HTN) and dyslipidemia (DSL), improvement in blood pressure, triglyceride and cholesterol levels was observed and all cases were able to decrease their medications. Regarding diabetic patients, insulin was stopped in all patients and replaced with oral hypoglycemic medication only (linagliptin). Renal graft function and proteinuria level decreased in all cases (100%). All patients claimed to have excellent quality of life. Conclusion LSG showed excellent outcomes regarding weight reduction, improvement and resolution of comorbidities, kidney function and quality of life in this high risk group of patients.

Sign in / Sign up

Export Citation Format

Share Document